Sage Therapeutics’ (SAGE) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $12.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on SAGE. Canaccord Genuity Group lifted their target price on Sage Therapeutics from $8.00 to $8.50 and gave the company a “hold” rating in a research report on Tuesday. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Monday. Bank of America began coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price objective for the company. Finally, Wall Street Zen cut shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 7th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.93.

Sage Therapeutics Price Performance

Shares of SAGE opened at $9.12 on Tuesday. The firm has a market capitalization of $571.09 million, a price-to-earnings ratio of -1.57 and a beta of 0.18. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $13.47. The company has a 50-day moving average of $7.07 and a 200 day moving average of $6.91.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to analysts’ expectations of $14.12 million. Sage Therapeutics had a negative return on equity of 68.99% and a negative net margin of 747.63%. The business’s revenue was up 78.0% compared to the same quarter last year. During the same period last year, the business posted ($1.80) earnings per share. On average, equities analysts anticipate that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SAGE. Millennium Management LLC grew its holdings in Sage Therapeutics by 8.3% in the fourth quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company’s stock worth $8,817,000 after purchasing an additional 124,720 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Sage Therapeutics by 31.2% in the 4th quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 4,350 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Sage Therapeutics by 108.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 38,876 shares during the last quarter. BNP Paribas Financial Markets increased its position in Sage Therapeutics by 9.3% during the 4th quarter. BNP Paribas Financial Markets now owns 77,560 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 6,574 shares in the last quarter. Finally, Jane Street Group LLC increased its position in Sage Therapeutics by 103.1% during the 4th quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company’s stock valued at $2,509,000 after buying an additional 234,528 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.